Kisplyx (Lenvatinib)

Lenvatinib inhibits multiple receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT. By blocking these receptors, it reduces tumor blood‑vessel formation, limits cell proliferation, and interferes with survival signals, thereby slowing or halting cancer growth.

The specific dose of Kisplyx is determined by the prescribing oncologist based on the patient’s cancer type, disease stage, renal and hepatic function, and other individual factors. The prescriber will select the appropriate strength and dosing schedule according to clinical guidelines.

Safety of lenvatinib in pregnancy and lactation has not been established. It is classified as contraindicated in pregnancy because potential fetal harm cannot be ruled out. Women of child‑bearing potential should use effective contraception, and breastfeeding is not recommended while on therapy.

To request Kisplyx, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Kisplyx (lenvatinib) differs from some alternatives by targeting a broader spectrum of kinases, including FGFRs in addition to VEGFRs and PDGFRα. This broader inhibition can provide efficacy in tumors that rely on multiple growth‑factor pathways, whereas other TKIs may focus on a narrower set of receptors.

Kisplyx should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in a bathroom or near heat sources, and keep the container tightly closed when not in use.

Kisplyx is taken orally, usually once daily, with or without food as directed by the treating physician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe hypertension, hepatic failure, arterial thromboembolic events, gastrointestinal perforation or fistula formation, and life‑threatening bleeding. Patients should be monitored closely for signs of these events, and any concerning symptoms should be reported to a healthcare professional immediately.

Kisplyx is contraindicated in patients who are pregnant, have uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to lenvatinib or any of its excipients. It should also be avoided in individuals taking strong CYP3A4 inducers without appropriate dose adjustments.